The US FDA approval of belimumab, the first new lupus drug in 50 years, highlights how genomics can contribute to drug discovery and shows that long-standing hurdles in trial design can be overcome.
This is a preview of subscription content, log in via an institution to check access.
References
Moore, P. A. et al. Science 285, 260–263 (1999).
Zhang, J. et al. J. Immunol. 166, 6–10 (2001).
Furie, R. A. et al. Arthritis Rheum. 61, 1143–1151 (2009).
Navarra, S. et al. Lancet 377, 721–731 (2011).
Rights and permissions
About this article
Cite this article
Landmark lupus approval opens door for next wave of drugs. Nat Rev Drug Discov 10, 243–245 (2011). https://doi.org/10.1038/nrd3413
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3413
- Springer Nature Limited